Day: March 16, 2023

Growing body of data supports Ampligen’s potential as both a prophylactic and an early-onset therapy against human Ebola virus disease outbreaks

OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced a late-breaking presentation at the 36^th International Conference on Antiviral Research (ICAR) detailing Ampligen’s mechanism of action in the treatment of Ebola virus disease (EVD).

The presentation was given by Angela Corona, PhD, Department of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy, and one of the published authors of a recent manuscript titled “Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action.” Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of EVD in Central Africa capable of reaching epidemic status. Highlights of the recently published Ampligen data that was presented include:

• As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection.
• Ampligen appears to inactivate the EBOV lethal factor (EBOV VP35), which is believed to be responsible, in part, for the high mortality rate observed in humans, by acting as a “competitive decoy.” VP35 is understood to sequester the dsRNA produced by EBOV during its replication, which inhibits the normal innate immune responses to viral infection.
• Ampligen protected mice from a lethal challenge by mouse adapted EBOV-Zaire and its associated weight loss.
• The 6 mg/kg doses, frequently used in AIM’s clinical trials, used in mouse model is easily achievable and well tolerated in humans.
• Overall, the data suggest Ampligen’s potential as a viable candidate to protect against exposure to EBOV.

The corresponding slides from the presentation at ICAR are now available on the Company’s website (aimimmuno.com) on the “Events and Presentations” page.

AIM CEO Thomas K. Equels commented, “In vivo pre-clinical analysis shows that Ampligen has potential as both a prophylactic and an early-onset therapeutic in Ebola virus disease. Animal studies with Ampligen at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories demonstrated 100% protective survival, as compared to 100% mortality in Ebola virus disease. Those animal studies are indicative of the drug’s high potential for efficacy. The analysis presented at ICAR now provides a clear understanding of why Ampligen is achieving such a high level of efficacy in these animal models, signaling its potential as a human therapy.”

Ampligen has been granted Orphan Drug status for Ebola virus disease by the European Medicines Agency and the FDA. Ampligen is not currently approved for the prevention or treatment of EVD.

The Company intends to file Investigational New Drug applications to study the use of Ampligen (1) as an early onset therapy for the treatment of EBOV, and (2) for the prevention of Ebola virus reactivation. Ultimately, the Company’s goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.

About the International Society for Antiviral Research (ISAR)

The International Society for Antiviral Research (ISAR) is an internationally recognized organization for scientists involved in basic, applied, and clinical aspects of antiviral research. The Society main event is the annual International Conference on Antiviral Research (ICAR), a truly interdisciplinary meeting which attracts the interest of chemists, biologists, and clinicians.

About Ampligen

Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is currently being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country. Ampligen is being used to treat pancreatic cancer patients in an Early Access Program approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center. Additionally, Ampligen is also approved in Argentina for the treatment of severe chronic fatigue syndrome and is currently being evaluated in SARS-CoV-2/COVID-19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID Conditions.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, an investigational new drug called Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being investigated for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The clinical study and other matters discussed above are subject to a number of unknowns including, but not limited to, that significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Ebola virus, comments and additional testing requested by the FDA if and when the Company files the Investigational New Drug application and whether the Company will be able to obtain a Tropical Disease Priority Review Voucher for the new drug application. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Two of the authors of the manuscript are officers or directors of the Company. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com

GlobeNewswire Distribution ID 8789385

• Zoom becomes Official Unified Communications Platform of MLB and Presenting Partner of MLB Replay Review
• MLB to introduce league-first, broadcast look-ins from the Zoom Replay Operations Center
• Zoom Contact Center, Zoom Events, and Zoom’s all-in-one collaboration platform will deliver unprecedented transparency to the fans and enhanced communications between front office staff, umpires, and league officials

SAN JOSE, Calif. and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) — Major League Baseball (MLB) and Zoom Video Communications, Inc. (NASDAQ: ZM) today announced a first-of-its-kind partnership for the league, aimed to enhance MLB games and the fan viewership experience. As the new Official Unified Communications Platform of MLB, Zoom Contact Center and the Zoom platform technology will power new elements of Major League games and broadcasts.

MLB Chief Operations & Strategy Officer Chris Marinak, said: “We are always looking for innovative ways to leverage best-in-class technology to advance the MLB experience and deliver more to our fans. Partnering with Zoom, a category leader that reinvented the way we connect, was a natural next step for us. We are excited to integrate Zoom Contact Center and other Zoom platform technology into our gameday operations and continue to modernize experiences in a secure, reliable, and innovative way.”

Zoom Chief Marketing Officer, Janine Pelosi said: “MLB brings together tens of millions of passionate fans every season. Zoom’s rapid pace of innovation and obsession with making human connection easier and better, is crucial to help MLB evolve its experience and deliver unprecedented transparency and access to its fans. With MLB leveraging Zoom Contact Center and Zoom’s all-in-one collaboration platform, we are able to truly show the world how a historical brand can continue to innovate and unlock new possibilities.”

Zoom platform integration drives MLB innovations:

• Zoom Contact Center transforms replay review – In the 2022 MLB season, there were more than 1,400 replay reviews. Historically, the league’s replay review was reliant on disparate technology and audio-only communication with umpires on the field, resulting in fans being disconnected from the decision-making process.

  Beginning with the 2023 Season, the Crew Chief, the most senior member of the four-man umpire crew, will connect to the Zoom Replay Operations Center using Zoom’s Contact Center solution during any replay review. During national broadcasts on MLB Network and Apple TV+, fans will also see the Zoom Replay Operations Center in action live during replay reviews and hear from an expert rules analyst who will discuss replay reviews with the broadcast team. MLB’s goal with this new setup is to create a more transparent and engaging review process.

• Zoom Platform helps streamline communication – Zoom will be used to securely deliver sensitive information in one of the most high-pressure and high-profile MLB Events, Day One of the 2023 MLB Draft.
• Broader league-wide Zoom integrations advance collaboration – Zoom’s all-in-one collaboration platform is integrated across several MLB clubs, platforms, and broadcast outlets. In addition to Zoom Meetings, many MLB teams are using Zoom Phone to stay connected with colleagues and customers, as well as Zoom Contact Center to deliver prompt, accurate, and highly personalized customer experiences to their fans. MLB’s corporate offices use Zoom Meetings, Zoom Rooms, Zoom Phone, and Zoom Webinar to connect, collaborate, and communicate.

To learn more about the Zoom platform and the technology that will power several new elements in MLB starting in the 2023 season, read the blog here.

About MLB
Major League Baseball (MLB) is the most historic professional sports league in the United States and consists of 30 member clubs in the U.S. and Canada, representing the highest level of professional baseball. Led by Commissioner Robert D. Manfred, Jr., MLB remains committed to making an impact in the communities of the U.S., Canada and throughout the world, perpetuating the sport’s larger role in society and permeating every facet of baseball’s business, marketing, community relations and social responsibility endeavors. MLB currently features record levels of competitive balance, continues to expand its global reach through programming and content to fans all over the world, and registered records in games and minutes watched this season on MLB.TV. With the continued success of MLB Network and MLB digital platforms, MLB continues to find innovative ways for its fans to enjoy America’s National Pastime and a truly global game. For more information on Major League Baseball, visit www.MLB.com.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

MLB Communications
David Hochman
david.hochman@mlb.com

Zoom Public Relations
Candace Dean
press@zoom.us

GlobeNewswire Distribution ID 8789553

IBFD Masterclass: Tax Structuring in Africa – Selected Critical Issues

Masterclass returns to strengthen African taxation

AMSTERDAM, March 16, 2023 (GLOBE NEWSWIRE)

—IBFD will host the Masterclass: Tax Structuring in Africa – Selected Critical Issues, on 22-23 May 2023 in Arusha, Tanzania for African tax practitioners. This advanced-level training will provide participants with a platform to learn, share and debate the most pressing issues in international taxation.

African tax professionals such as tax managers and directors, in-house tax and accounting specialists in commerce and industry, practitioners in tax advisory firms, and government officials, will gain a deeper and practical understanding of the most important topics in international taxation, from a unique African perspective.

Which topics will the Masterclass programme cover?

• Current Issues in International Taxation and Transfer Pricing from Around the Globe – Impact on African Inbound and Outbound Investments
• Tax Treaty Policy in Africa: Impact of Treaty Anti-Avoidance Rules
• Artificial Avoidance of Permanent Establishments: Experience from Around the Globe and Potential Lessons for Africa
• Cross-Border Business Activities in Africa – Cross-Border Services and Withholding Tax Structuring

Find out more and benefit from the early-bird discount!
For more details on the programme objectives, course content, structure, trainers and to benefit from the 10% early-bird discount ending 20 March, visit https://www.ibfd.org/events/ibfd-masterclass-tax-structuring-africa-selected-critical-issues.

Contact information: Phil Windus, Senior Marketing Coordinator: p.windus@ibfd.org.

About IBFD
IBFD is a leading international provider of cross-border tax expertise, with a long-standing history of supporting and contributing to tax research and academic activities. As an independent foundation, IBFD utilizes its global network of tax experts and its Knowledge Centre to serve Fortune 500 companies, governments, international consultancy firms and tax advisers.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/10031abf-1cae-4f2c-98ba-32a73ce8caae

GlobeNewswire Distribution ID 8789135